Cover Image

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Emil Kumar, Jessica Okosun
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
by: Rui Sun, et al.
Published: (2026)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
by: Giacomo Loseto, et al.
Published: (2025)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
by: Monia Marchetti, et al.
Published: (2025)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
by: Fenghua Gao, et al.
Published: (2025)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
by: A. Zduniak, et al.
Published: (2024)

Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy
by: Nan Wang, et al.
Published: (2024)

Current Status of Revisions to the Lugano Classification in Lymphoma
Published: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Published: (2026)

581 | THE BURDEN OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN ENGLAND: A RETROSPECTIVE ANALYSIS OF REAL‐WORD TREATMENT PATTERNS AND OUTCOMES
by: A. Zaffalon, et al.
Published: (2025)

596 | THE BURDEN OF RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA IN ENGLAND: A RETROSPECTIVE ANALYSIS OF REAL‐WORD TREATMENT PATTERNS AND OUTCOMES
by: A. Zaffalon, et al.
Published: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
by: Sang Eun Yoon, et al.
Published: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
by: Oskar Steinbrecher, et al.
Published: (2024)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
by: Rafaella Cabral Samico, et al.
Published: (2025)

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
by: Peter Borchmann, et al.
Published: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
by: Hazim S. Ababneh, et al.
Published: (2024)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
by: Yue Zhao, et al.
Published: (2025)

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches
by: Sonali M. Smith
Published: (2025)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
by: Simone Ferrero, et al.
Published: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
by: Chuanming Lin, et al.
Published: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
by: Gabriela Forestieri, et al.
Published: (2024)

Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
Published: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
by: Meirav Kedmi, et al.
Published: (2024)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
by: Allison M. Bock, et al.
Published: (2024)

Causal Associations of Gut Microbiota Species With Lymphoma: A Two‐Sample Mendelian Randomization Study
by: Mei Li, et al.
Published: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
by: Lotte Nygård, et al.
Published: (2025)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
by: Yan Li, et al.
Published: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
by: Juliette Penichoux, et al.
Published: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
by: Yutaka Shimazu, et al.
Published: (2025)

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience
by: Hala Bekhit, et al.
Published: (2025)

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
by: James R. Cerhan, et al.
Published: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
by: Minna Harmanen, et al.
Published: (2025)

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First‐Line Chemotherapy in Patients With Lymphoma
by: Charlotte Nørregaard Grønset, et al.
Published: (2025)

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
by: Pallawi Torka, et al.
Published: (2025)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
by: E. Silkenstedt, et al.
Published: (2025)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
by: Pier Luigi Zinzani, et al.
Published: (2025)

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study
by: John L. Vaughn, et al.
Published: (2026)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
by: Youwen Zhu, et al.
Published: (2026)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
by: Inna Y. Gong, et al.
Published: (2026)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
by: Hazim S. Ababneh, et al.
Published: (2024)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
by: Tengfei Shi, et al.
Published: (2025)